Fennec Pharmaceuticals CEO Jeffrey Hackman Receives Award

What Happened

• Jeffrey S. Hackman, CEO of Fennec Pharmaceuticals (FENC), was credited with 1,159 shares on 2026-06-30 under an award/acquisition (SEC code A). The reported acquisition price was $0.00, so no cash was paid — these were restricted shares becoming unrestricted.

Key Details

• Transaction date: 2026-06-30; Form 4 filed: 2026-07-01 (timely filing).
• Transaction type/code: A (grant, award or other acquisition).
• Shares acquired: 1,159 at $0.00 (total reported value $0).
• Footnote: F1 — these shares were released from restriction from shares originally awarded 3/28/2025.
• Shares owned after transaction: not specified in the provided filing excerpt.
• No indication of a sale, market purchase, 10b5-1 plan, or tax-withholding reported in this excerpt.

Context

• This action represents a release of restriction (likely vesting or satisfaction of award conditions) rather than an open-market buy or sale. Such releases increase the insider's freely tradable shares but are not itself a cash investment signal.